Point/counterpoint: Should full agonist opioid medications be offered to hospitalized patients for management of opioid withdrawal?
J Hosp Med
.
2024 Apr;19(4):339-343.
doi: 10.1002/jhm.13238.
Epub 2023 Nov 29.
Authors
Sam J Stern
1
2
,
Joseph L D'Orazio
3
4
,
Brian D Work
1
5
,
Susan L Calcaterra
6
,
Ashish P Thakrar
7
8
Affiliations
1
Division of Hospital Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
2
Lewis Katz School of Medicine, Center for Urban Bioethics, Philadelphia, Pennsylvania, USA.
3
Cooper Center for Healing, Camden, New Jersey, USA.
4
Department of Emergency Medicine, Division of Toxicology and Addiction Medicine, Cooper Medical School of Rowan University, Camden, New Jersey, USA.
5
Prevention Point Philadelphia, Philadelphia, Pennsylvania, USA.
6
Division of General Internal Medicine and Hospital Medicine, University of Colorado, Aurora, Colorado, USA.
7
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
8
Perelman School of Medicine, Center for Addiction Medicine and Policy, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
PMID:
38030816
PMCID:
PMC10987259
(available on
2024-10-01
)
DOI:
10.1002/jhm.13238
No abstract available
MeSH terms
Analgesics, Opioid / adverse effects
Buprenorphine* / therapeutic use
Humans
Substance Withdrawal Syndrome* / drug therapy
Substances
Analgesics, Opioid
Buprenorphine
Grants and funding
K08 DA049905/DA/NIDA NIH HHS/United States